ReviewCurrent dermatology reports2014
Merkel Cell Carcinoma: Epidemiology, Target, and Therapy.
Review in Current dermatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Effectiveness and Safety of Treatments for Early-Stage Merkel Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies.Cancer medicine · 2025Pooled it
- The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Trial
- MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review.Diagnostics (Basel, Switzerland) · 2025Review
- Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.International journal of molecular sciences · 2024Review
- Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell KillingACS biomaterials science & engineering · 2023Article
- Article
- Combined Merkel Cell Carcinoma with Nodal Presentation: Report of a Case Diagnosed with Excisional but Not Incisional Biopsy and Literature Review.Diagnostics (Basel, Switzerland) · 2023Article
- Multimodality imaging findings of infection-induced tumors.Abdominal radiology (New York) · 2022Review
- Wide local excision for Merkel cell carcinoma of the lower extremity: A case report.Experimental and therapeutic medicine · 2022Article
- Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.Journal for immunotherapy of cancer · 2022Article
- Review
- Treatment of locally advanced cutaneous Merkel cell carcinoma with topical imiquimod.JAAD case reports · 2021Article
- Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program.Journal of translational medicine · 2021Article
- Article
- Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Gene expression profile identifies distinct molecular subtypes and potential therapeutic genes in Merkel cell carcinoma.Translational oncology · 2020Article
- Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.The oncologist · 2019Review
- Cancer-testis antigens as biomarkers for Merkel cell carcinoma: Pitfalls and opportunities.Journal of cutaneous pathology · 2019Article
- Review
- Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma.BMJ case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine tumor of the skin with a rising incidence. MCC has metastatic potential regardless the size of the primary tumor and a 5-year disease associated mortality rate is 46 %. Surgery and radiation are the mainstays of management for primary MCC. There is no evidence-based effective chemotherapy for recurrent or metastatic diseases to date. In-depth mechanistic studies in MCC have uncovered important cellular events and the association with a polyomavirus, which has provided direct evidence for molecular targeted and immunotherapy. Further perspective studies and clinical trials are warranted to provide reliable evidence of possible pitfalls and effectiveness of molecular targeted immunotherapy alone or in combination with chemotherapy in MCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.